Puma Biotechnology Inc - Common Stock (PBYI)

Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy.

A strong buy rating carries weight which speculative investors may want to research in these strong buy stocks under $5.

The company's CEO bought $2.5 million worth of company stock.

A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to cancer treatment.

PBYI stock results show that Puma Biotechnology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.

Gainers Lytus Technologies Holdings PTV. Ltd. (NASDAQ: LYT) shares surged 39.3% to $0.6621 in pre-market trading after gaining around 14% on Wednesday.

It's time to start off the day with a breakdown of the biggest pre-market stock movers worth watching on Thursday morning!

Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront payment of $90 million.

Penny stocks tend to be more volatile than more so-called “established” stocks, so you have to be comfortable with your risk tolerance.

Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.

It may have benefited from positive news about another company's drug candidate.

Gainers AEye, Inc. (NASDAQ: LIDR) shares jumped 50% to close at $1.25 on Friday. AEye recently posted a Q3 loss of $0.11 per share.

Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash.